VP‐16–213 salvage therapy for refractory germinal neoplasms

Stephen D. Williams, Lawrence H. Einhorn, F. Anthony Greco, Robert Oldham, Ronald Fletcher

Research output: Contribution to journalArticle

133 Scopus citations

Abstract

Thirty-three patients with advanced refractory germinal neoplasms were treated with VP-16-213 alone or in combination with cis-platinum, bleomycin, and frequently Adriamycin. All had prior chemotherapy, which in most was extensive. There were 14 complete and 15 partial remissions. Five of the patients with partial remission were rendered disease free by resection of residual tumor. Eleven remain disease free from 6 +-23+ months. Toxicity was considerable. One-third were hospitalized for fever and granulocytopenia and four had life-threatening thrombocytopenia. There was one drug-related death. VP-16 is an active drug in germinal neoplasms. It appears to be an important component of 'salvage' regimens for refractory patients, but severe toxicity may ensue.

Original languageEnglish (US)
Pages (from-to)2154-2158
Number of pages5
JournalCancer
Volume46
Issue number10
DOIs
StatePublished - Nov 15 1980

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'VP‐16–213 salvage therapy for refractory germinal neoplasms'. Together they form a unique fingerprint.

  • Cite this